Dr Sanjiv Agarwala analyzes data from 2 studies showing that the first-line combination of nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses, as well as improved overall survival compared with monotherapy, in patients with metastatic uveal melanoma.
Learn more about our family of publications.
View Our Publications